Effects of estrogen on vascular inflammation: A matter of timing

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 8, 2012, Pages 2035-2042

  Novella, Susana ^a,c,d   Heras, Magda ^b   Hermenegildo, Carlos ^c,d   Dantas, Ana Paula ^a,b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

estrogen; menopause; multiplex immunoassay; raloxifene; vascular inflammation

Indexed keywords

BIOLOGICAL MARKER; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; INTERLEUKIN 1BETA; RALOXIFENE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGING; ANTIINFLAMMATORY ACTIVITY; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE ARTERY; VASCULITIS;

ADULT; AGED; AGING; BIOLOGICAL MARKERS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; HUMANS; INTERLEUKIN-6; MENOPAUSE; MIDDLE AGED; RALOXIFENE; TIME FACTORS; VASCULITIS;

EID: 84864285699     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.250308     Document Type: Article

References (43)

1. Granger DN, Vowinkel T, Petnehazy T. Modulation of the inflammatory response in cardiovascular disease. Hypertension. 2004;43:924-931. (Pubitemid 38579889)
2. Tostes RC, Nigro D, Fortes ZB, Carvalho MH. Effects of estrogen on the vascular system. Braz J Med Biol Res. 2003;36:1143-1158. (Pubitemid 37236237)
3. Straub RH. The complex role of estrogens in inflammation. Endocr Rev. 2007;28:521-574. (Pubitemid 47236336)
4. Störk S, van der Schouw YT, Grobbee DE, Bots ML. Estrogen, inflammation and cardiovascular risk in women: a critical appraisal. Trends Endocrinol Metab. 2004;15:66-72. (Pubitemid 38253008)
5. Cutolo M, Capellino S, Sulli A, Serioli B, Secchi ME, Villaggio B, Straub RH. Estrogens and autoimmune diseases. Ann N Y Acad Sci. 2006;1089:538-547. (Pubitemid 47092097)
6. Störk S, Baumann K, von Schacky C, Angerer P. The effect of 17 beta-estradiol on MCP-1 serum levels in postmenopausal women. Cardiovasc Res. 2002;53:642-649. (Pubitemid 34175257)
7. Störk S, von Schacky C, Angerer P. The effect of 17beta-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial. Atherosclerosis. 2002;165:301-307. (Pubitemid 35333356)
8. Harman SM. Estrogen replACEment in menopausal women: recent and current prospective studies, the WHI and the KEEPS. Gend Med. 2006;3:254-269. (Pubitemid 46923558)
9. Singh T, Newman AB. Inflammatory markers in population studies of aging. Ageing Res Rev. 2011;10:319-329.
10. Seals DR, Jablonski KL, Donato AJ. Aging and vascular endothelial function in humans. Clin Sci. 2011;120:357-375.
11. Csiszar A, Wang M, Lakatta EG, Ungvari Z. Inflammation and endothelial dysfunction during aging: role of NF-kappaB. J Appl Physiol. 2008;105:1333-1341.
12. Donato AJ, Black AD, Jablonski KL, Gano LB, Seals DR. Aging is associated with greater nuclear NF kappa B, reduced I kappa B alpha, and increased expression of proinflammatory cytokines in vascular endothelial cells of healthy humans. Aging Cell. 2008;7:805-812. (Pubitemid 352749435)
13. Bruunsgaard H, Pedersen M, Pedersen BK. Aging and proinflammatory cytokines. Curr Opin Hematol. 2001;8:131-136. (Pubitemid 32324632)
14. Yanaka M, Honma T, Sato K, Shinohara N, Ito J, Tanaka Y, Tsuduki T, Ikeda I. Increased monocytic adhesion by senescence in human umbilical vein endothelial cells. Biosci Biotechnol Biochem. 2011;75:1098-1103.
15. Frink RJ. Gender gap, inflammation and acute coronary disease: are women resistant to atheroma growth? Observations at autopsy. J Invasive Cardiol. 2009;21:270-277.
16. Pereira TM, Nogueira BV, Lima LC, Porto ML, Arruda JA, Vasquez EC, Meyrelles SS. Cardiac and vascular changes in elderly atherosclerotic mice: the influence of gender. Lipids Health Dis. 2010;9:87.
17. Surra JC, Guillén N, Arbonés-Mainar JM, Barranquero C, Navarro MA, Arnal C, Orman I, Segovia JC, Osada J. Sex as a profound modifier of atherosclerotic lesion development in apolipoprotein E-deficient mice with different genetic backgrounds. J Atheroscler Thromb. 2010;17:712-721.
18. Holm P, Andersen HL, Arrøe G, Stender S. Gender gap in aortic cholesterol accumulation in cholesterol-clamped rabbits: role of the endothelium and mononuclear-endothelial cell interaction. Circulation. 1998;98:2731-2737. (Pubitemid 28564009)
19. Kip KE, Marroquin OC, Shaw LJ, Arant CB, Wessel TR, Olson MB, Johnson BD, Mulukutla S, Sopko G, Merz CN, Reis SE. Global inflammation predicts cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Am Heart J. 2005;150:900-906. (Pubitemid 41607761)
20. Sumino H, Ichikawa S, Ohyama Y, Takahashi T, Saito Y, Nakamura T, Kanda T, Kurabayashi M. Effect of transdermal hormone replACEment therapy on the monocyte chemoattractant protein-1 concentrations and other vascular inflammatory markers and on endothelial function in postmenopausal women. Am J Cardiol. 2005;96:148-153. (Pubitemid 40853961)
21. Friedrich EB, Clever YP, Wassmann S, Hess C, Nickenig G. 17Beta-estradiol inhibits monocyte adhesion via down-regulation of Rac1 GTPase. J Mol Cell Cardiol. 2006;40:87-95. (Pubitemid 43012120)
22. Arenas IA, Armstrong SJ, Xu Y, Davidge ST. Tumor necrosis factor-alpha and vascular angiotensin II in estrogen-deficient rats. Hypertension. 2006;48:497-503. (Pubitemid 44253746)
23. Sunday L, Tran MM, Krause DN, Duckles SP. Estrogen and progestagens differentially modulate vascular proinflammatory factors. Am J Physiol Endocrinol Metab. 2006;291:E261-E267. (Pubitemid 44035284)
24. Dubey RK, Imthurn B, Barton M, Jackson EK. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res. 2005;66:295-306. (Pubitemid 40471044)
25. Novensa L, Selent J, Pastor M, Sandberg K, Heras M, Dantas AP. Equine estrogens impair nitric oxide production and endothelial nitric oxide synthase transcription in human endothelial cells compared with the natural 17{beta}-estradiol. Hypertension. 2010;56:405-411.
26. Abdullah KN, Raoof A, Raoof M. Effectiveness and safety of raloxifene in post-menopausal females. J Coll Physicians Surg Pak. 2005;15:266-269. (Pubitemid 40883270)
27. Sbarouni E, Flevari P, Kroupis C, Kyriakides ZS, Koniavitou K, Kremastinos DT. The effects of raloxifene and simvastatin on plasma lipids and endothelium. Cardiovasc Drugs Ther. 2003;17:319-323. (Pubitemid 37500183)
28. Francucci CM, Camilletti A, Boscaro M. Raloxifene and cardiovascular health: its relationship to lipid and glucose metabolism, hemostatic and inflammation factors and cardiovascular function in postmenopausal women. Curr Pharm Des. 2005;11:4187-4206. (Pubitemid 41679181)
29. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465-1477. (Pubitemid 46556472)
30. Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J, Brzyski R, Allison M, Ockene J, Sarto G, Rossouw JE. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol. 2009;170:12-23.
31. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt). 2006;15:35-44. (Pubitemid 43192860)
32. Wynne FL, Payne JA, Cain AE, Reckelhoff JF, Khalil RA. Age-related reduction in estrogen receptor-mediated mechanisms of vascular relaxation in female spontaneously hypertensive rats. Hypertension. 2004;43:405-412. (Pubitemid 38174147)
33. LeBlanc AJ, Reyes R, Kang LS, Dailey RA, Stallone JN, Moningka NC, Muller-Delp JM. Estrogen replACEment restores flow-induced vasodilation in coronary arterioles of aged and ovariectomized rats. Am J Physiol Regul Integr Comp Physiol. 2009;297:R1713-R1723.
34. Lekontseva ON, Rueda-Clausen CF, Morton JS, Davidge ST. Ovariectomy in aged versus young rats augments matrix metalloproteinase-mediated vasoconstriction in mesenteric arteries. Menopause. 2010;17:516-523.
35. Cann JA, Register TC, Adams MR, St Clair RW, Espeland MA, Williams JK. Timing of estrogen replACEment influences atherosclerosis progression and plaque leukocyte populations in APOE-/-mice. Atherosclerosis. 2008;201:43-52.
36. Karatzis EN. The role of inflammatory agents in endothelial function and their contribution to atherosclerosis. Hellenic J Cardiol. 2005;46:232-239. (Pubitemid 41664060)
37. Schreyer SA, Vick CM, LeBoeuf RC. Loss of lymphotoxin-alpha but not tumor necrosis factor-alpha reduces atherosclerosis in mice. J Biol Chem. 2002;277:12364-12368. (Pubitemid 34952808)
38. Schreyer SA, Peschon JJ, LeBoeuf RC. Accelerated atherosclerosis in mice lacking tumor necrosis factor receptor p55. J Biol Chem. 1996;271:26174-26178. (Pubitemid 26347463)
39. Kim J, Kim JY, Song KS, Lee YH, Seo JS, Jelinek J, Goldschmidt-Clermont PJ, Issa JP. Epigenetic changes in estrogen receptor beta gene in atherosclerotic cardiovascular tissues and in-vitro vascular senescence. Biochim Biophys Acta. 2007;1772:72-80. (Pubitemid 44960730)
40. Novensà L, Novella S, Medina P, Segarra G, Castillo N, Heras M, Hermenegildo C, Dantas AP. Aging negatively affects estrogens-mediated effects on nitric oxide bioavailability by shifting ERa/ERß balance in female mice. PLoS ONE. 2011;6:e25335.
41. Kim KH, Toomre D, Bender Jr. Splice isoform estrogen receptors as integral transmembrane proteins. Mol Biol Cell. 2011;22:4415-4423.
42. Li L, Haynes MP, Bender Jr. Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc Natl Acad Sci USA. 2003;100:4807-4812. (Pubitemid 36457810)
43. Flouriot G, Brand H, Denger S, Metivier R, Kos M, Reid G, Sonntag-Buck V, Gannon F. Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1. EMBO J. 2000;19:4688-4700.